BRAF and metastatic colorectal cancer: Moreover, in some patients with metastatic colorectal cancer with the BRAF V600E mutation, the combination of encorafenib, cetuximab, and binimetinib significantly prolonged overall survival and demonstrated a high response rate compared to the standard therapy [21].